Hydrocad

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hydrocad

What is Hydrocad? (Identity, Composition, and Purpose)

Hydrocad is a prescription-only medication supplied as an Oral Tablet containing the active substance Hydroxychloroquine Sulfate. It is classified as both an Antimalarial Agent and a Disease-Modifying Anti-Rheumatic Drug (DMARD), a designation clinically utilized for its significance in managing certain systemic conditions.


Quick Facts

Property Description
Active ingredient Hydroxychloroquine Sulfate (INN)
Form Oral Tablet
Pharmacological class Antimalarial, DMARD
Common use Systemic autoimmune disease, malaria prevention/treatment
Origin Synthetic, 4-aminoquinoline derivative

Classification, Form, and Origin

The medicine is manufactured as a synthetic, single-ingredient Oral Tablet for oral administration. The therapeutic compound, Hydroxychloroquine Sulfate, is a derivative of the 4-aminoquinoline family. Unlike simple anti-inflammatory agents, the drug's long-recognized immunomodulatory effects contribute to providing long-term systemic control over the underlying disease activity. The drug is a therapeutic option for autoimmune diseases, especially systemic lupus erythematosus and rheumatoid arthritis.

General Purpose and Action

The primary purpose of Hydrocad is to help moderate an overactive immune system and, separately, to act as a blood schizonticide to manage susceptible parasitic malaria infections. In its immunomodulatory role, the drug functions as a weak base, accumulating within specific cell compartments to dampen the excessive inflammatory responses observed in chronic autoimmune conditions. This mechanism helps to stabilize the body's overall response, mitigating the inflammatory damage. A typical use scenario involves its prescription to manage the symptoms and progression of chronic inflammatory conditions where an immunomodulatory effect is required.

What side effects are possible with Hydrocad?

Possible Side Effects and Safety Information

The regulatory safety profile for Hydrocad (Hydroxychloroquine Sulfate) organizes potential effects by frequency and system involvement, focusing on critical adverse reactions documented in official prescribing information.

Frequency and System-Organ Classes

The most frequently reported effects, classified as Common in regulatory documents, include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and headache. Effects classified as Uncommon include certain skin reactions like rash and hair loss (alopecia), as well as nervous system effects like dizziness.

Major physiological systems officially documented as being affected include:

  • Eye Disorders: Primarily concerning the retina (retinopathy) and cornea.
  • Cardiac Disorders: Including cardiomyopathy and disturbances in heart rhythm.
  • Blood and Lymphatic System Disorders: Rare but serious reactions like aplastic anemia and agranulocytosis.
  • Skin and Subcutaneous Tissue Disorders: Including severe cutaneous adverse reactions (SCARs).

Serious Adverse Reactions and Safety Patterns

Serious Adverse Reactions highlighted in regulatory warnings include the potential for irreversible retinopathy, which is explicitly tied to the total cumulative dose and duration of use. Cardiotoxicity, such as serious ventricular arrhythmias, and life-threatening hepatic failure have also been documented in post-marketing reports.

Special safety considerations are documented for certain populations. Caution is advised for individuals with renal or hepatic impairment due to the risk of accumulation. Furthermore, the official label notes an increased risk of hemolytic anemia in patients with G6PD deficiency and advises caution regarding pre-existing conditions like Psoriasis. The regulatory basis for treatment requires a baseline and periodic ophthalmological examination to monitor for ocular toxicity, establishing a clear safety constraint.

Overdose and Emergency Response

Hydrocad (Hydroxychloroquine Sulfate) overdose is classified by regulatory authorities as a medical emergency due to the potential for rapid, life-threatening toxicity. The documented overdose profile includes manifestations such as visual disturbances, headache, and somnolence. Acute toxicity is associated with severe cardiovascular collapse, marked hypotension, and dangerous conduction disorders like QRS/QT prolongation. Severe and fatal outcomes have been reported, primarily due to the development of ventricular arrhythmias, including Torsades de Pointes, and CNS effects such as seizures and coma. A critical laboratory finding in overdose cases is severe hypokalemia.

Regulators mandate that immediate medical attention or emergency services be contacted for any suspected overdose. Hospital monitoring is required for continuous observation and intervention. No specific antidote is known for Hydrocad overdose; management is based on symptomatic and supportive treatment, including procedures like early gastric lavage, administration of activated charcoal, and continuous cardiac monitoring (ECG). Overdose poses a particularly dangerous risk to children, which can rapidly lead to death.

Therapeutic Uses of Hydrocad

The primary role of Hydrocad (Hydroxychloroquine Sulfate) is to provide supportive relief when symptoms interfere with routine activities across two distinct therapeutic domains. It is commonly used to help with conditions involving episodic or fluctuating manifestations. The relevant clinical contexts include Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), and the treatment or prevention of certain types of malaria.

Managing Chronic Autoimmune Disease Activity

This medication is generally used across conditions presenting with episodic or fluctuating manifestations, particularly SLE and RA. It is applied in addressing symptoms related to inflammatory or irritative states, which include persistent physical discomfort, swelling, and symptoms that interfere with daily functioning. This use supports patients during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms, which may assist with maintaining functional stability.

Treatment and Prevention of Susceptible Malaria

Hydrocad is also applied across domains where additional symptomatic support is needed in the context of parasitic infection. It is relevant for managing symptoms that interfere with daily comfort, such as the fever and systemic distress associated with an uncomplicated malarial attack. Furthermore, it is commonly used to help with prophylaxis in relevant clinical settings, which is applied in scenarios where additional management of discomfort is required.


Quick Fact: Symptomatic Support for Joint Discomfort

Hydrocad is applied in scenarios where additional management of discomfort is required in chronic inflammatory conditions.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Hydrocad?

This section summarizes the official population eligibility and non-eligibility information for Hydrocad (Hydroxychloroquine Sulfate) as documented by governmental regulatory authorities.


Eligibility Scope

Classification Population Rule (Official Regulatory Wording)
Contraindicated Patients with known hypersensitivity to 4-aminoquinoline compounds or pre-existing retinal or visual field changes due to any 4-aminoquinoline drug. The medicine is also contraindicated for long-term use in children.
Allowed (Standard Use) Adults for SLE, RA, and CDLE. Adult and pediatric patients for malaria treatment/prophylaxis in non-resistant areas.
Restricted/Caution Use requires caution in patients with renal, hepatic, or cardiac impairment. Patients with Psoriasis or Porphyria have restricted eligibility, as use may officially exacerbate these conditions.
Not Recommended Children for SLE/RA treatment, as safety and efficacy have not been established. Low-weight pediatric patients for malaria treatment due to dosing constraints.

Condition-Based Restrictions

Official labeling mandates that use in patients with Diabetes requires caution due to the risk of hypoglycemia. Pregnancy and lactation status dictates conditional use only after careful balancing of the potential benefits against possible hazards, as the drug is excreted in human milk.

What should I know about interactions with other medicines?

The official regulatory profile for Hydrocad (Hydroxychloroquine Sulfate) establishes specific constraints when co-administered with other medicinal products. These interactions are classified based on their mechanism and resulting clinical significance.

Contraindicated and High-Risk Combinations

Co-administration with other medicines that have the potential to prolong the QT interval is formally contraindicated due to the documented additive risk of ventricular arrhythmias. A significant pharmacodynamic interaction exists with antidiabetic or hypoglycemic agents, which can lead to an enhanced blood-glucose-lowering effect and a formal risk of severe hypoglycemia. The concomitant use of the drug with Tamoxifen Citrate or other substances known to cause retinal toxicity requires caution due to the documented additive risk of irreversible retinal damage.

Metabolic and Administration Constraints

Hydrocad is documented as an inhibitor of the CYP2D6 enzyme, a pharmacokinetic interaction that can increase the plasma concentration of co-administered medicines that are CYP2D6 substrates. Similarly, the medicine is a weak inhibitor of P-glycoprotein (P-gp), which may increase the exposure of P-gp substrate medicines such as Cyclosporine or Digoxin. Furthermore, non-absorbable substances like antacids and kaolin may reduce the medicine's oral absorption; therefore, a mandatory separation period of at least four hours is required between administration of these products. Caution is also noted for patients with underlying hepatic disease or alcoholism, as these conditions may increase the severity of certain drug interactions.

Mechanism of Action

How Hydrocad Works

The mechanism of Hydroxychloroquine Sulfate (Hydrocad) involves two distinct domains: systemic immunomodulation and antiparasitic activity, both dependent on the drug's fundamental chemical property as a weak base.


Modulating Immune Signals via Intracellular pH

The primary mechanism relies on the drug acting as a proton trap within the acidic organelles (endosomes and lysosomes) of immune cells, increasing their internal pH. This critical pH alteration physically inhibits the activation of key immune sensors like Toll-like Receptors ( TLR7/9) and impairs the function of related enzymes (e.g., PLA2). This action suppresses the cell's ability to process antigens and synthesize major pro-inflammatory mediators, resulting in decreased systemic production of Type I Interferons and cytokines and alteration of inflammatory pathway signaling.


Blocking Parasite Detoxification

Separate from its immunomodulatory role, the drug exerts an antiparasitic effect by accumulating in the acidic food vacuole of susceptible malaria parasites. It binds to the toxic metabolic byproduct heme, preventing the parasite from converting it into harmless hemozoin. This blockade of heme polymerization causes the accumulation of toxic free heme, which disrupts the parasite’s internal systems and is the mechanism for antiparasitic toxicity in the blood stage.

Dosage and Administration Information

Administration Guidelines

Hydrocad is administered by the oral route as a tablet. The medicine should be swallowed whole and is recommended to be taken with a meal or a glass of milk to support proper intake and minimize gastric upset.

For the management of chronic autoimmune conditions, the dosing schedule begins with an initial range of 400 mg to 600 mg per day. This is then typically reduced to a lower maintenance dose of 200 mg to 400 mg daily, administered as a single dose or in two divided doses. A crucial administrative constraint for long-term use is the maximum daily dose, which must not exceed 6.5 mg/kg of the patient’s ideal body weight, or 400 mg daily, whichever is less.

Because of the drug’s cumulative action, treatment for chronic disease is generally long-term, with guidance recommending discontinuation if no beneficial effect is observed by approximately six months.

For malaria prophylaxis, Hydrocad is used in a cyclic pattern, with a standard adult dose of 400 mg taken once a week. This regimen requires the weekly dose to begin two weeks prior to travel and continue for a full four weeks after leaving the endemic area. The 200 mg tablet strength is not suitable for pediatric patients weighing less than 31 kg. The protocol for a missed prophylaxis dose is to take it as soon as remembered and continue the original schedule.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Hydrocad

Evidence for Use in Systemic Lupus Erythematosus (SLE)

Research examined the use of Hydrocad in individuals with Systemic Lupus Erythematosus, a condition characterized by fluctuating or episodic manifestations. Research in this area has utilized both Randomized Controlled Trials (RCTs) and large Long-term Observational Cohort Studies and monitored its application in adults with established SLE. Studies monitored outcomes related to systemic or functional imbalance, such as changes in standardized measurements of disease activity and the occurrence of acute disease exacerbations, or flares.

Studies reported data show patterns related to a difference in the observed frequency of heightened symptom activity in patient cohorts continuing the regimen compared to those who discontinued it. Long-term observational research explored outcomes such as survival rates and the rate of organ damage accrual. However, research findings describe group patterns, and data for certain specific subgroups, such as older adults with multiple other health conditions, remain insufficient for strong conclusions.

Evidence for Use in Rheumatoid Arthritis (RA)

Research examined Hydrocad’s use in individuals with established Rheumatoid Arthritis, a condition marked by functional limitations and inflammatory or irritative states. Studies monitored its observation alongside other conventional treatments. The available evidence includes Randomized Controlled Trials that research examined outcomes related to physical discomfort and daily functioning.

Findings indicate that studies conducted during periods of increased symptom activity reported patterns related to measured differences in outcomes related to joint pain and swelling in patients receiving the medicine. A key research limitation is the potential for slow evolution of symptom changes, which may complicate the interpretation of results from trials with limited follow-up durations.

Evidence for Use in Malaria (Treatment and Prevention)

Hydrocad was studied for use in both the treatment of acute malaria and its prevention (prophylaxis). Research examined the drug’s role in measured changes in parasite counts in the blood, as well as its observed role in prevention of infection. Studies report that the medicine was studied for its effect on parasite burden of the blood forms of specific susceptible Plasmodium parasites.

Outcomes in prevention vary significantly based on the geographic region and the type of Plasmodium strain present. The primary uncertainty is that results apply only to the specific parasite strains studied, as widespread drug resistance patterns remain a key limitation.

Key Studies & References

  1. NIH MedlinePlus Drug Information on Hydroxychloroquine
  2. Clinical and immunological effects of hydroxychloroquine in patients with active rheumatoid arthritis despite antirheumatic treatment

Frequently Asked Questions (FAQ)

Common questions about Hydrocad (FAQ)

Q: How quickly should I expect to notice anything after starting Hydrocad?

According to official product information, Hydrocad is known to work slowly. For chronic conditions like rheumatoid arthritis or lupus, the full therapeutic benefit may take several weeks to become noticeable, and it could take up to six months to observe the maximum effect.


Q: Is Hydrocad the same kind of drug as [Competitor Drug Name]? What's the main difference?

Regulatory documents classify Hydrocad (Hydroxychloroquine Sulfate) as a 4-aminoquinoline derivative. It is formally designated as both an Antimalarial Agent and a Disease-Modifying Anti-Rheumatic Drug (DMARD). This classification describes its specific actions as defined in regulatory documents.


Q: Does Hydrocad interact badly with common pain relievers like ibuprofen?

Official documentation mentions that Hydrocad may be used safely in combination with certain non-steroidal anti-inflammatory drugs (NSAIDs) and other antirheumatic agents. However, information on co-administration advises that all drug combinations be professionally monitored, as specific checks for interactions may be indicated.


Q: Do I need to change my diet while I am taking Hydrocad?

Official guidance recommends taking the medicine with a meal or a glass of milk to help minimize stomach upset. Specific, formally mandated dietary changes are not typically listed in regulatory documents. Some official patient information mentions that avoiding consumption of coffee, alcohol, or spicy foods may help reduce stomach irritation, but this is a general consideration.


Q: How long does Hydrocad typically stay in my system?

Hydrocad is known to be eliminated very slowly from the body. Official pharmacokinetic data indicates that the terminal half-life—the time it takes for half of the drug to be eliminated—is long, ranging from approximately 40 to 50 days after chronic use.


Q: Can I drink alcohol moderately while on Hydrocad?

Official patient information notes that caution regarding alcohol consumption is relevant. Underlying hepatic disease, which can be linked to alcoholism, is noted as potentially increasing the risk of severe drug interactions. Alcohol may also increase the likelihood of experiencing gastrointestinal irritation.


Q: Why do doctors prescribe Hydrocad instead of other options?

Hydrocad is prescribed because of its classification as a Disease-Modifying Anti-Rheumatic Drug (DMARD) and its recognized immunomodulatory activity. It functions to help stabilize an overactive immune system, making it an established option for managing chronic conditions like lupus and rheumatoid arthritis.


Q: Is Hydrocad safe to take if I am already on blood pressure medication?

Regulatory warnings indicate caution is necessary when co-administering Hydrocad with other medicines that may prolong the QT interval (affecting heart rhythm). It can also increase the concentration of medicines that are metabolized by the CYP2D6 enzyme. Regulatory constraints emphasize the importance of professional review for all existing medications.


Q: Can Hydrocad affect my ability to drive or operate machinery?

Yes, official safety information warns that Hydrocad may impair the ability of the eye to focus (accommodation) and can cause blurring of vision. Regulatory documents state that caution may be necessary when performing tasks that require concentration, such as driving or operating machinery.


Q: Does Hydrocad make you gain weight?

Weight gain is not formally listed as a common or uncommon side effect in regulatory adverse reaction documents. However, official warnings regarding changes in mood or potential nervous system effects are documented.


Q: Does Hydrocad interact with birth control pills?

Regulatory documents detail a specific interaction with the progestin drospirenone, which is an ingredient in certain oral contraceptives. This combination can potentially increase the risk of high potassium levels (hyperkalemia). Interactions with other specific formulations are typically not detailed.


Q: Can taking Hydrocad cause changes in my mood or sleep?

Official warnings note that Hydrocad may cause new or increased suicidal thoughts, depression, anxiety, or other unusual changes in mood or behavior. Sleep disturbances, such as insomnia, have also been reported in official adverse reaction documents.


Q: Does Hydrocad have any warnings for elderly patients?

General regulatory guidance and patient information often indicate that there is a higher chance of experiencing side effects in patients 65 years old and older. Increased caution and professional monitoring are typically constraints noted for this population.


Q: If I feel better, can I stop taking Hydrocad without consulting a professional?

For chronic autoimmune conditions, Hydrocad is intended for long-term management. The decision to discontinue or change dosage is an action requiring professional guidance. Official guidance states that abrupt discontinuation for chronic conditions should only be done under the direction of a healthcare professional.


Q: Does Hydrocad interact with herbal remedies or vitamins?

Specific herbal remedies and vitamins are generally not listed in drug interaction sections. However, Hydrocad is described as an inhibitor of the CYP2D6 enzyme, meaning it may potentially interact with any co-administered products that are substrates of this enzyme. This may include various co-administered products.


Q: Does Hydrocad lose its effectiveness over time?

The medicine is designed for sustained use in chronic conditions. Research in rheumatoid arthritis patients has shown that treatment is sometimes terminated due to a lack of adequate disease control over time, but this finding does not specifically indicate tachyphylaxis (a loss of the drug's initial efficacy).


Q: Does Hydrocad cause sensitivity to the sun?

Hydrocad is associated with certain skin reactions. Official documentation includes sun sensitivity (photosensitivity) as a documented dermatological side effect. Information regarding the risk of sun exposure is therefore relevant for patients using this medicine.


Q: Can I take Hydrocad with my morning coffee?

Hydrocad must be taken with a meal or a glass of milk to aid intake. While coffee is not formally contraindicated, some patient guidance mentions that avoiding coffee or other caffeinated products around the time of dosing may help minimize potential stomach irritation.


Q: Does Hydrocad have a specific Black Box Warning?

The FDA’s official labeling includes a 'WARNINGS AND PRECAUTIONS' section that highlights serious risks. These include the potential for irreversible retinal toxicity (retinopathy) and cardiomyopathy, which are considered critical safety constraints.


Q: What kind of specialist usually prescribes Hydrocad?

The medicine is primarily prescribed for autoimmune diseases and is most commonly initiated and monitored by specialists in rheumatology (for conditions like lupus and arthritis) or dermatology (for specific skin conditions). Management may then continue in primary care.


Q: Does Hydrocad show up on drug tests?

Hydroxychloroquine is not generally a substance targeted in standard drug of abuse panels. However, toxicology data suggests that extremely high concentrations of the compound, such as in overdose situations, have been observed to potentially interfere with some common laboratory assays.


Q: Is Hydrocad expensive, or is a generic version available?

Hydrocad is the brand name for the active substance, Hydroxychloroquine Sulfate. Official drug product databases confirm that a generic version of Hydroxychloroquine Sulfate is available in many regulated markets.


Q: Are there any official reports of people misusing Hydrocad?

Official health advisories have been issued to caution against the inappropriate use of Hydrocad (or related compounds) in non-pharmaceutical forms or without a prescription. These advisories emphasize the high risk of severe toxicity and serious health consequences from misuse.

How should Hydrocad be stored and disposed of?

Official Storage and Disposal Requirements

Hydrocad (Hydroxychloroquine Sulfate) tablets must be stored according to specific regulatory standards to ensure product stability and safety. The required storage environment is Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted temperature excursions up to 30 C (86 F). The medication must be kept in a tight, light-resistant container and stored in its original packaging to protect the active ingredient.

A mandatory requirement from regulatory labeling is to keep Hydrocad out of the sight and reach of children due to the high risk of accidental ingestion. Disposal of any unused or expired tablets must follow official local regulations or community drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hydrocad found in:

A-Z Index: